pSivida’s lead investigational new product is a three-year sustained-release implant containing fluocinolone acetonide , a corticosteroid, in late stage clinical development for the treatment of posterior uveitis. The product utilizes the proven Durasert Technology platform. The first Phase 3 study achieved its primary endpoint with high statistical significance. The second Phase 3 study results are expected first half of 2017. Filing in the EU is anticipated first half of 2017 and second half of 2017 in the U.S.
- pSivida Corp. Announces First Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
- pSivida and Nicox Enter Strategic Collaboration Agreement to Develop Sustained Release Drug to Lower Intraocular Pressure in Patients with Glaucoma
- pSivida Partners with Global Pharmaceuticals Company to Develop Sustained Release Formulations of Glaucoma Drugs